|
시장보고서
상품코드
1964479
G-CSF 및 G-CSF 바이오시밀러 시장 규모, 점유율, 성장 분석 : 약물 유형별, 치료 용도별, 유통 경로별, 지역별 - 업계 예측(2026-2033년)G-CSF and G-CSF Biosimilars Market Size, Share, and Growth Analysis, By Drug Type (G-CSF, Biosimilars), By Therapeutic Application (Oncology, Blood Disorders), By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의G-CSF 및 G-CSF 바이오시밀러 시장 규모는 2024년에 56억 달러로 평가되었으며, 2025년 60억 3,000만 달러에서 2033년까지 108억 3,000만 달러로 성장할 전망입니다. 예측 기간(2026-2033년) 동안 CAGR은 7.6%로 예측됩니다.
세계G-CSF 및 G-CSF 바이오시밀러 시장은 주로 오리지널 생물학적 제제의 특허 만료와 저렴한 가격의 지지적 종양학 치료에 대한 수요 증가에 의해 주도되고 있습니다. 이미 확립된G-CSF 제품은 눈에 띄는 임상적 이점을 보여줬으며, 자르키오와 우데니카와 같은 바이오시밀러의 등장을 가능하게 했습니다. 이는 경쟁력 있는 가격 책정을 촉진하고 환자 접근성을 확대하는 데 기여하고 있습니다. 이러한 변화로 인해 시장은 가격에 민감한 영역으로 변모하고 있으며, 병원들이 저가의 바이오시밀러를 채택하는 움직임이 가속화되고 있습니다. 그 결과, 치료 순응도가 향상되고 입원율이 감소하고 있습니다. 또한, AI 통합을 통해 수요 예측과 제조 공정이 개선되어 업무 효율이 향상되었습니다. 이를 통해 합리적인 가격 책정이 더욱 뒷받침되고 있습니다. 그 결과, 시장은 생산 투자 및 신흥 애플리케이션 개발에 있어 더욱 매력적인 환경이 되었으며, 이 분야의 지속적인 성장으로 가는 길이 열리고 있습니다.
세계G-CSF 및 G-CSF 바이오시밀러 시장을 주도하는 요인들
암 환자의 증가 추세와 골수억제성 화학요법의 광범위한 사용과 함께 화학요법 유발성 호중구감소증을 예방하고 관리하는 치료법에 대한 임상적 수요가 크게 증가하고 있습니다. 이러한 추세는G-CSF 및 바이오시밀러 시장의 성장을 주도하고 있습니다. 임상 가이드라인과 의료진들의 진료 관행은 치료 강도를 유지하고 감염 위험을 최소화하기 위해 예방적 투여와 치료적 투여의 중요성을 강조하고 있으며, 이는 처방 빈도 증가로 이어지고 있습니다. 또한, 임상의들이 바이오시밀러의 선택에 익숙해지고 의료 기관이 이러한 약물을 통합하는 프로토콜을 채택함에 따라 미충족 수요가 효과적으로 해결되어 시장의 지속적인 확장을 가져오고 있습니다.
세계G-CSF 및 G-CSF 바이오시밀러 시장의 제약 조건
세계G-CSF 및 G-CSF 바이오시밀러 시장은 유사성을 입증하기 위한 복잡하고 다양한 규제 요건과 상호 교환성에 대한 국가별 기준의 차이로 인해 심각한 도전에 직면해 있습니다. 이러한 요인들이 복잡하게 얽혀 잠재적 개발자들의 의욕을 떨어뜨리고, 각 시장으로의 제품 출시를 지연시킬 수 있습니다. 개발자는 종합적인 비교시험 수행, 승인 후 모니터링 책임 이행, 끊임없이 변화하는 규제에 대한 적응이 요구되며, 이 모든 것은 개발 기간의 연장, 증거 창출 및 규제 당국과의 대화에 대한 지속적인 투자를 필요로 합니다. 이러한 복잡한 승인 절차는 결국 새로운 바이오시밀러의 진입을 방해하고, 시장의 광범위한 보급과 성장을 촉진할 수 있는 경쟁적 역학을 제한하고 있습니다.
세계G-CSF 및 G-CSF 바이오시밀러 시장 동향
세계G-CSF 및 G-CSF 바이오시밀러 시장에서는 의료 시스템 및 종양센터가 지지요법을 재택 치료로 전환하는 움직임에 따라 외래 치료로 큰 변화가 일어나고 있습니다. 이러한 추세는 환자의 편의성을 우선시하고 입원 수요를 줄이는 것을 목표로 하고 있으며, 제조업체는 투약 형태 혁신, 개인화된 환자 지원 프로그램 구축, 외래 치료용 물류 강화에 힘쓰고 있습니다. 또한, 환자의 복약 순응도 및 모니터링을 보장하기 위해 전문 약국과 의료 서비스 제공자 간의 협력이 필수적으로 요구되고 있습니다. 분산형 케어가 표준화되면서G-CSF 가치사슬 전반의 안정성, 사용 편의성, 통합 서비스 제공에 대한 기대가 높아지고 있으며, 이것이 시장 역학을 형성하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의G-CSF 및 G-CSF 바이오시밀러 시장 규모 : 약물 유형별 & CAGR(2026-2033년)
세계의G-CSF 및 G-CSF 바이오시밀러 시장 규모 : 치료 용도별 & CAGR(2026-2033년)
세계의G-CSF 및 G-CSF 바이오시밀러 시장 규모 : 유통 채널별 & CAGR(2026-2033년)
세계의G-CSF 및 G-CSF 바이오시밀러 시장 규모 & CAGR(2026-2033년)
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.03.23Global G-Csf And G-Csf Biosimilars Market size was valued at USD 5.6 Billion in 2024 and is poised to grow from USD 6.03 Billion in 2025 to USD 10.83 Billion by 2033, growing at a CAGR of 7.6% during the forecast period (2026-2033).
The global G-CSF and G-CSF biosimilars market is primarily propelled by the expiration of patents for original biologics and the increasing demand for accessible supportive oncology care. Established G-CSF products have shown significant clinical benefits, enabling the emergence of biosimilars like Zarxio and Udenyca, which foster competitive pricing and broaden patient access. This shift has transformed the market into a price-sensitive arena, encouraging hospitals to adopt lower-cost biosimilars, resulting in better treatment adherence and reduced hospitalization rates. Additionally, the integration of AI enhances operational efficiencies by improving demand forecasting and manufacturing processes, further supporting affordability. As a result, the market becomes more attractive for production investments and exploration of emerging applications, paving the way for sustained growth in the sector.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global G-Csf And G-Csf Biosimilars market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global G-Csf And G-Csf Biosimilars Market Segments Analysis
Global g-csf and g-csf biosimilars market is segmented by drug type, therapeutic application, distribution channel and region. Based on drug type, the market is segmented into G-CSF, Biosimilars, Hormones and Others. Based on therapeutic application, the market is segmented into Oncology, Blood Disorders, Chronic Diseases, Endocrine Disorders and Others. Based on distribution channel, the market is segmented into Online Pharmacies and Offline. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global G-Csf And G-Csf Biosimilars Market
The increasing prevalence of cancer, coupled with the extensive use of myelosuppressive chemotherapy, has significantly heightened the clinical demand for treatments that prevent and manage chemotherapy-induced neutropenia. This trend is driving growth in the G-CSF and biosimilars market. Clinical guidelines and the practices of healthcare providers highlight the importance of both preventive and therapeutic administration to sustain treatment intensity and minimize the risk of infections, leading to more frequent prescriptions. Additionally, as clinicians become more acquainted with biosimilar options and institutions adopt protocols integrating these drugs, unmet clinical needs are being effectively addressed, resulting in sustained market expansion.
Restraints in the Global G-Csf And G-Csf Biosimilars Market
The Global G-CSF and G-CSF biosimilars market faces significant challenges due to complex and varied regulatory requirements for demonstrating similarity, coupled with differing national standards for interchangeability. These factors contribute to an intricate landscape that can discourage potential developers and delay the introduction of products to various markets. Developers are required to create comprehensive comparative studies, fulfill post-approval monitoring responsibilities, and adapt to constantly changing regulations, all of which can extend development timelines and necessitate ongoing investments in both evidence generation and regulatory dialogue. This intricate approval process ultimately hinders the entry of new biosimilars, limiting competitive dynamics that could otherwise drive broader adoption and growth in the market.
Market Trends of the Global G-Csf And G-Csf Biosimilars Market
The Global G-Csf and G-Csf Biosimilars market is witnessing a significant shift towards outpatient therapies, driven by healthcare systems and oncology centers transitioning supportive care to home-based settings. This trend prioritizes patient convenience and aims to reduce inpatient demand, prompting manufacturers to innovate delivery formats, create tailored patient support programs, and enhance logistics for ambulatory care. Additionally, partnerships between specialty pharmacies and healthcare providers are becoming essential to ensure patient adherence and monitoring. As decentralized care becomes the norm, there is an increasing expectation for stability, ease of use, and integrated services throughout the G-Csf value chain, shaping market dynamics.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global G-CSF and G-CSF Biosimilars Market Size by Drug Type & CAGR (2026-2033)
- Market Overview
- G-CSF
- Biosimilars
- Hormones
- Others
Global G-CSF and G-CSF Biosimilars Market Size by Therapeutic Application & CAGR (2026-2033)
- Market Overview
- Oncology
- Blood Disorders
- Chronic Diseases
- Endocrine Disorders
- Others
Global G-CSF and G-CSF Biosimilars Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Online Pharmacies
- Offline
- Hospital Pharmacies
- Retail Pharmacies
Global G-CSF and G-CSF Biosimilars Market Size & CAGR (2026-2033)
- North America (Drug Type, Therapeutic Application, Distribution Channel)
- US
- Canada
- Europe (Drug Type, Therapeutic Application, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Type, Therapeutic Application, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Type, Therapeutic Application, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Type, Therapeutic Application, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioGeneriX AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intas Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biocon Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celltrion Healthcare Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fresenius Kabi AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Cadila
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Accord Healthcare Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Coherus BioSciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Emcure Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Samsung Bioepis Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GSK plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
